Literature DB >> 3358889

The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers.

A R Aitkenhead1, E S Lin, K J Achola.   

Abstract

The pharmacokinetics of nalbuphine were studied in 10 healthy volunteers on two separate occasions following administration by either the intravenous (20 mg) or oral (60 mg) route. After administration, serum concentrations of nalbuphine were measured for 12 h using a high pressure liquid chromatography assay, and pharmacokinetic parameters were derived using a three compartment model. After i.v. administration, elimination half-life was 222 (111-460) min (mean and range) and total body clearance was 1.5 (0.8-2.3) 1 min-1.Cmax after oral administration was 21.4 (6.0-36.2) ng ml-1 and tmax was 46.6 (15.3-89.0) min. Bioavailability of the oral preparation was 11.8 (6.1-20.1)%.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3358889      PMCID: PMC1386483          DOI: 10.1111/j.1365-2125.1988.tb03300.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Evaluation of nalbuphine for abuse potential.

Authors:  D R Jasinski; P A Mansky
Journal:  Clin Pharmacol Ther       Date:  1972 Jan-Feb       Impact factor: 6.875

2.  Pharmacokinetics and pharmacodynamics.

Authors:  C J Hull
Journal:  Br J Anaesth       Date:  1979-07       Impact factor: 9.166

3.  Nalbuphine and droperidol combination for local standby sedation.

Authors:  D S Klein
Journal:  Anesthesiology       Date:  1983-04       Impact factor: 7.892

4.  Analgesic effect of intramuscular and oral nalbuphine in postoperative pain.

Authors:  W T Beaver; G A Feise; D Robb
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

5.  Oral and rectal nalbuphine bioavailability: first-pass metabolism in rats and dogs.

Authors:  B J Aungst; G Lam; E Shefter
Journal:  Biopharm Drug Dispos       Date:  1985 Oct-Dec       Impact factor: 1.627

6.  Ceiling effect for respiratory depression by nalbuphine.

Authors:  A Romagnoli; A S Keats
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

7.  High-performance liquid chromatographic analysis of plasma levels of nalbuphine in cardiac surgical patients.

Authors:  C L Lake; C A DiFazio; E N Duckworth; J C Moscicki; J S Engle; C G Durbin
Journal:  J Chromatogr       Date:  1982-12-10

8.  Determination of nalbuphine in human plasma by automated high-performance liquid chromatography with electrochemical detection.

Authors:  M W Lo; G P Juergens; C C Whitney
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1984-01

9.  Anesthetic potency of nalbuphine and interaction with morphine in rats.

Authors:  C A DiFazio; J C Moscicki; M R Magruder
Journal:  Anesth Analg       Date:  1981-09       Impact factor: 5.108

10.  The enflurane sparing effect of morphine, butorphanol, and nalbuphine.

Authors:  M R Murphy; C C Hug
Journal:  Anesthesiology       Date:  1982-12       Impact factor: 7.892

View more
  7 in total

1.  Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans.

Authors:  Hong-Jaan Wang; Cheng-Huei Hsiong; Shung-Tai Ho; Min-Jen Lin; Tung-Yuan Shih; Pei-Wei Huang; Oliver Yoa-Pu Hu
Journal:  Pharm Res       Date:  2014-02-14       Impact factor: 4.200

Review 2.  Patient-controlled analgesia. Pharmacokinetic and therapeutic considerations.

Authors:  H F Hill; L E Mather
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

3.  [Analgesia with opioids in the paediatric patient.].

Authors:  C Schlünder
Journal:  Schmerz       Date:  1992-12       Impact factor: 1.107

4.  A mechanistic model for the sex-specific response to nalbuphine and naloxone in postoperative pain.

Authors:  Smita Kshirsagar; Robert Gear; Jon Levine; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-18       Impact factor: 2.745

5.  Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus.

Authors:  Amale Hawi; Harry Alcorn; Jolene Berg; Carey Hines; Howard Hait; Thomas Sciascia
Journal:  BMC Nephrol       Date:  2015-04-08       Impact factor: 2.388

6.  Pharmacometric Analysis of Intranasal and Intravenous Nalbuphine to Optimize Pain Management in Infants.

Authors:  Miriam Pfiffner; Eva Berger-Olah; Priska Vonbach; Marc Pfister; Verena Gotta
Journal:  Front Pediatr       Date:  2022-03-02       Impact factor: 3.418

7.  Comparison of Side Effects of Nalbuphine and Morphine in the Treatment of Pain in children with Cancer: A Prospective Study.

Authors:  Anna Kubica-Cielińska; Michał Czapla; Raúl Juárez-Vela; Clara Isabel Tejada-Garrido; Marzena Zielińska
Journal:  Cancers (Basel)       Date:  2022-07-25       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.